Sagimet Biosciences (SGMT) Cash from Financing Activities: 2023-2024
Historic Cash from Financing Activities for Sagimet Biosciences (SGMT) over the last 1 years, with Jun 2024 value amounting to -$27,000.
- Sagimet Biosciences' Cash from Financing Activities rose 97.03% to -$27,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $191.1 million, marking a year-over-year change of. This contributed to the annual value of $104.8 million for FY2024, which is 21.65% up from last year.
- Per Sagimet Biosciences' latest filing, its Cash from Financing Activities stood at -$27,000 for Q2 2024, which was down 100.03% from $104.8 million recorded in Q1 2024.
- Sagimet Biosciences' Cash from Financing Activities' 5-year high stood at $104.8 million during Q1 2024, with a 5-year trough of -$910,000 in Q2 2023.
- In the last 2 years, Sagimet Biosciences' Cash from Financing Activities had a median value of -$27,000 in 2024 and averaged $38.2 million.
- Data for Sagimet Biosciences' Cash from Financing Activities shows a peak YoY soared of 77,192.65% (in 2024) over the last 5 years.
- Over the past 2 years, Sagimet Biosciences' Cash from Financing Activities (Quarterly) stood at $87.2 million in 2023, then spiked by 97.03% to -$27,000 in 2024.
- Its Cash from Financing Activities was -$27,000 in Q2 2024, compared to $104.8 million in Q1 2024 and $87.2 million in Q3 2023.